HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

Abstract:

:HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure were generally excluded in the existing trials and a different patient population with a distinct pattern of morbidity and treatment was studied. In addition, no safety data are available for statins in patients with heart failure, where there are potential concerns about coenzyme Q10 depletion and excessive low-density lipoprotein reduction. This review summarises the clinical and preclinical evidence for potential beneficial effects of statins in CHF. In experimental systems, statins have been shown to improve cardiac function through antioxidative and anti-inflammatory action. Statins improve endothelial function, may reduce neurohormonal activation, and stimulate endothelial progenitor cells. Some of these effects occur independently of cholesterol lowering and can be explained by inhibition of isoprenylation of signal transducing proteins of the family of Rho guanosine triphosphatases. Two ongoing controlled randomised trials (CORONA [Controlled Rosuvastatin Multinational Study in Heart Failure] and GISSI-HF [Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico--Heart Failure]) will help us to assess whether the described beneficial effects of statins in heart failure outweigh the potential negative effects and translate into the reduction of clinical endpoints.

journal_name

Drugs

journal_title

Drugs

authors

Laufs U,Custodis F,Böhm M

doi

10.2165/00003495-200666020-00002

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

145-54

issue

2

eissn

0012-6667

issn

1179-1950

pii

6622

journal_volume

66

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Microbiological evaluation of cefpodoxime proxetil.

    abstract::Cefpodoxime, the active de-esterified molecule of the orally absorbable cephalosporin cefpodoxime proxetil, inhibits streptococci, Neisseria spp., and most Enterobacteriaceae, with MIC50 and/or MIC90 values of less than or equal to 2 mg/L; with regard to the latter family of bacteria, the MIC50 and/or MIC90 values of ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199100423-00004

    authors: Wiedemann B,Luhmer E,Zühlsdorf MT

    更新日期:1991-01-01 00:00:00

  • Inotuzumab Ozogamicin: First Global Approval.

    abstract::Intravenous inotuzumab ozogamicin (Besponsa®; Pfizer) is an anti-CD22 monoclonal antibody-calicheamicin conjugate that binds to CD22-expressing tumour cells. Upon binding, the complex is internalised and the cytotoxic calicheamicin derivative is released inside the cell, inducing double-strand DNA breakage and subsequ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0802-5

    authors: Lamb YN

    更新日期:2017-09-01 00:00:00

  • Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

    abstract::Iloprost is an analogue of epoprostenol (prostacyclin; PGI2; a potent but short-lived prostanoid mainly produced in the vascular endothelium) and mimics the pharmacodynamic properties of this compound, namely: inhibition of platelet aggregation, vasodilatation and, as yet ill-defined, cytoprotection. Improved metaboli...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243060-00008

    authors: Grant SM,Goa KL

    更新日期:1992-06-01 00:00:00

  • Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

    abstract::Isradipine, a dihydropyridine derivative, inhibits the inward calcium flux through 'slow' channels of cardiac and vascular tissue, thereby eliciting potent coronary, cerebral and peripheral vasodilatation. In comparison with other calcium channel blockers the drug offers the advantages of minimal cardiodepressant acti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040010-00004

    authors: Fitton A,Benfield P

    更新日期:1990-07-01 00:00:00

  • Tuberculosis vaccines: current progress.

    abstract::Tuberculosis continues to be a major cause of disease and death throughout the developing world. Chemotherapy is the current method of control but with the continuing emergence of drug resistance, coupled with the reticence of major drug companies to invest in drug discovery, the identification of new vaccines to comb...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200565170-00002

    authors: Orme IM

    更新日期:2005-01-01 00:00:00

  • Management of cystitis in young women.

    abstract::The common clinical problem of recurrent symptomatic urinary tract infections (UTI) in young women may be inconvenient and distressing to both the patient and her family, particularly if the infections are not managed in a rational manner. A suggested approach is included in table 1. ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197713020-00003

    authors: Bailey RR

    更新日期:1977-02-01 00:00:00

  • Albumin-bound Paclitaxel: in metastatic breast cancer.

    abstract::A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells. Intravenous nab-paclitaxel 260 mg/m(2) had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distributi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200666070-00007

    authors: Robinson DM,Keating GM

    更新日期:2006-01-01 00:00:00

  • Management of insomnia in patients with chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a common medical disorder, which causes considerable morbidity and mortality. Given the chronic and symptomatic nature of the disease, the patient is often seen in the physician's office with complaints of dyspnea. However, more than 50% of COPD patients also have sleep ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363040-00004

    authors: George CF,Bayliff CD

    更新日期:2003-01-01 00:00:00

  • Issues in patient compliance.

    abstract::Patient compliance refers to the willingness and ability of an individual to follow health-related advice, to take medication as prescribed, to attend scheduled clinic appointments and to complete recommended investigations. It is a major health issue, with outcomes related to levels of morbidity, mortality and cost u...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754060-00002

    authors: Murphy J,Coster G

    更新日期:1997-12-01 00:00:00

  • Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.

    abstract::The number of effective cytotoxic agents for the treatment of patients with metastatic adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy. For the subgroup of patients with inoperable gastrointestinal stromal tumour (GIST), progress has been made...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565020-00002

    authors: Hartmann JT,Patel S

    更新日期:2005-01-01 00:00:00

  • Tofacitinib: A Review in Rheumatoid Arthritis.

    abstract::Tofacitinib (Xeljanz®) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3. In the EU, oral tofacitinib 5 mg twice daily is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are int...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0835-9

    authors: Dhillon S

    更新日期:2017-12-01 00:00:00

  • Digoxin use in congestive heart failure. Current status.

    abstract::The use of digitalis in congestive heart failure with normal sinus rhythm is still debated. While older uncontrolled, withdrawal studies from 1969 to 1983 provided incomplete data, with poorly documented clinical status and poor haemodynamic and exercise data, some patients did improve clinically when digitalis treatm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855060-00002

    authors: Riaz K,Forker AD

    更新日期:1998-06-01 00:00:00

  • Treatment of the chronic fatigue syndrome. A review and practical guide.

    abstract::The chronic fatigue syndrome (CFS) was formally defined in 1988 to describe a syndrome of severe and disabling fatigue of uncertain aetiology associated with a variable number of somatic and/or psychological symptoms. CFS has been reported in most industrialised countries and is most prevalent in women aged between 20...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346040-00005

    authors: Blondel-Hill E,Shafran SD

    更新日期:1993-10-01 00:00:00

  • Management of gastroenteritis in early childhood.

    abstract::The most important aspect of modern management of acute diarrhoeal illness in children is that of oral rehydration therapy, and drug therapy is very rarely indicated. Despite the dramatic decline in mortality and morbidity in recent years, there is still the need for continuing education in the appropriate use of oral...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199244010-00005

    authors: Davies A,Jenkins HR

    更新日期:1992-07-01 00:00:00

  • The role of anaerobic bacteria in mediastinitis.

    abstract::The management of mediastinitis involves directing appropriate antibacterial therapy against the potential bacterial pathogens. The increased recovery of anaerobic bacteria from mediastinal infections has led to a greater appreciation of their role in this condition and to re-evaluation of the proper treatment of this...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666030-00004

    authors: Brook I

    更新日期:2006-01-01 00:00:00

  • Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

    abstract::Gatifloxacin (Tequin) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis, gonorrhoea and uncomplicated skin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565050-00007

    authors: Keam SJ,Croom KF,Keating GM

    更新日期:2005-01-01 00:00:00

  • Migalastat: First Global Approval.

    abstract::Migalastat (Galafold™)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Fabry disease is a rare disorder that results in a deficiency or absen...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-016-0607-y

    authors: Markham A

    更新日期:2016-07-01 00:00:00

  • Chemotherapy in the management of bladder tumours.

    abstract::For patients with superficial bladder tumours intravesical treatment or prophylaxis with thiotepa, doxorubicin, mitomycin C or Bacillus Calmette-Guerin has added a useful dimension to management, although the precise indications for each regimen remain to be better defined. For patients with metastatic bladder cancer ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198938020-00009

    authors: Whitmore WF Jr,Yagoda A

    更新日期:1989-08-01 00:00:00

  • Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

    abstract::Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus ma...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0421-y

    authors: Keating GM

    更新日期:2015-07-01 00:00:00

  • Potential immunological action of purine nucleoside analogues.

    abstract::Purine nucleoside analogues are a new class of drugs with activity against nondividing lymphocytes; thus, they should play a major role in the treatment of low grade lymphoid malignancies. As these drugs are active against resting lymphocytes, harmful effects related to this action were expected and have been reported...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400476-00009

    authors: Dighiero G

    更新日期:1994-01-01 00:00:00

  • Cidofovir.

    abstract::Cidofovir is a nucleotide analogue which inhibits viral DNA polymerase and is effective against human cytomegalovirus (CMV) infection. It is phosphorylated to its active form by cellular enzymes. With the long intracellular half-life of its metabolites, cidofovir can be administered weekly during induction and every o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652020-00006

    authors: Lea AP,Bryson HM

    更新日期:1996-08-01 00:00:00

  • Are All Dopamine Agonists Essentially the Same?

    abstract::Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01103-2

    authors: Torti M,Bravi D,Vacca L,Stocchi F

    更新日期:2019-05-01 00:00:00

  • Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

    abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00046

    authors: Monassier JP,Hanssen M

    更新日期:1987-01-01 00:00:00

  • New and Emerging Therapies for Alopecia Areata.

    abstract::Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01293-0

    authors: Pourang A,Mesinkovska NA

    更新日期:2020-05-01 00:00:00

  • The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.

    abstract::Until recently, patients with advanced thyroid cancers had limited options for systemic treatment. With the introduction of tyrosine kinase inhibitors (TKIs) as a promising new class of targeted therapies for thyroid cancer, suddenly patients with advanced disease were given new options to extend survival. Guidelines ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-017-0733-1

    authors: Lirov R,Worden FP,Cohen MS

    更新日期:2017-05-01 00:00:00

  • Ciclesonide nasal spray: in allergic rhinitis.

    abstract::Ciclesonide nasal spray delivers the corticosteroid ciclesonide as a hypotonic spray via a metered-dose manual pump. Systemic exposure to ciclesonide and its active metabolite desisobutyryl-ciclesonide is low after intranasal administration. High protein binding (approximately 99%) and rapid first-pass clearance furth...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868060-00009

    authors: Dhillon S,Wagstaff AJ

    更新日期:2008-01-01 00:00:00

  • Effect of nedocromil sodium on the bronchoconstrictor effect of neurokinin A in asthmatics.

    abstract::In a double-blind, crossover study we have investigated the effect of nedocromil sodium on neurokinin A (NKA)-induced bronchoconstriction in asthmatics. 12 patients with mild asthma inhaled either nedocromil sodium 4mg or placebo, on 2 separate days, as 2 puffs from a metered-dose aerosol 30 minutes before challenge w...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198900371-00019

    authors: Joos GF,Pauwels RA,Van der Straeten ME

    更新日期:1989-01-01 00:00:00

  • Long-term growth hormone replacement therapy in hypopituitary adults.

    abstract::Growth hormone deficiency (GHD) in the adult has now been fully recognised as a clinical entity characterised by abnormal body composition, osteopenia, impaired quality of life, cardiac dysfunction and an adverse lipid profile. While short-term studies of GH replacement have demonstrated irrefutably a favourable effec...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262160-00006

    authors: Verhelst J,Abs R

    更新日期:2002-01-01 00:00:00

  • Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent.

    abstract::Multiple drugs are now available for the treatment of overactive bladder. Currently, the pharmacological approach is to deal with the problem at the neuromuscular junction by attempting to stop the activity of the neurotransmitter with antimuscarinic medications. This article reviews the positive and negative aspects ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666100-00005

    authors: Appell RA

    更新日期:2006-01-01 00:00:00

  • Somatropin (Zorbtive): in short bowel syndrome.

    abstract::A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464120-00008

    authors: Keating GM,Wellington K

    更新日期:2004-01-01 00:00:00